Severe immune-related hyperthermia followed by immune-related pneumonitis with PD-1 inhibitor (sintilimab) in small cell lung cancer: A case report

被引：12
|
作者：
Li, Yi-hui [1 ]
Zhou, Yang [1 ]
Liu, Yuan-yuan [1 ]
Zhang, Guang-ju [1 ]
Xiao, Lei [1 ]
Li, Na [1 ]
Qin, Hai-feng [2 ]
Wang, Jian-gong [1 ]
Zhang, Li [3 ]
机构：
[1] Tangshan Peoples Hosp, Dept Multimodal Therapy Oncol, 65 Shengli Rd, Tangshan 063000, Hebei, Peoples R China
[2] Nanyuan Dist 302 Hosp PLA, Dept Pulm Neoplasm Internal Med, Beijing, Peoples R China
[3] Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Resp, Beijing, Peoples R China
来源：
THORACIC CANCER | 2021年 / 12卷 / 11期
关键词：
small cell lung cancer; immune checkpoint inhibitors; sintilimab; hyperthermia; immune‐ related pneumonitis; ADVERSE EVENTS; PROFILES;
D O I：
10.1111/1759-7714.13967
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Immune checkpoint inhibitors (ICIs) have achieved prominent efficacy in the treatment of numerous cancers, which is the most significant breakthrough in cancer therapy in recent years. However, ICIs are associated with a series of immune-related adverse events (irAEs). Pneumonitis is an uncommon but potentially fatal irAE. In the case reported here, a patient with advanced small cell lung cancer (SCLC) had rapid progression of disease following chemotherapy and received ICIs. The patient experienced severe immune-related hyperthermia followed by immune-related pneumonitis. Fortunately, a good clinical response was achieved after the patient received corticosteroids and tocilizumab.
引用
收藏
页码：1780 / 1783
页数：4
相关论文
共 50 条
  • [41] An autopsy case of immune-related severe colitis due to long-term use of nivolumab in a patient with non-small cell lung cancer
    Fujikawa, Masashi
    Tajiri, Tomoko
    Takemura, Masaya
    Nakao, Kenju
    Yamamoto, Sayaka
    Takeda, Norihisa
    Fukumitsu, Kensuke
    Fukuda, Satoshi
    Kamemitsu, Yoshihiro
    Uemura, Takehiro
    Ohkubo, Hirotsugu
    Maeno, Ken
    Ito, Yutaka
    Oguri, Tetsuya
    Niimi, Akio
    RESPIRATORY MEDICINE CASE REPORTS, 2022, 39
  • [42] Immune checkpoint inhibitor-related pneumonitis in non-small cell lung cancer: A review
    Hao, Yuxuan
    Zhang, Xiaoye
    Yu, Li
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [43] Prognostic Impact and Risk Factors of Immune-Related Pneumonitis in Patients With Non-Small-Cell Lung Cancer Who Received Programmed Death 1 Inhibitors
    Fukihara, Jun
    Sakamoto, Koji
    Koyama, Junji
    Ito, Takayasu
    Iwano, Shingo
    Morise, Masahiro
    Ogawa, Masahiro
    Kondoh, Yasuhiro
    Kimura, Tomoki
    Hashimoto, Naozumi
    Hasegawa, Yoshinori
    CLINICAL LUNG CANCER, 2019, 20 (06) : 442 - +
  • [44] Successful immune checkpoint inhibitor rechallenge after immune-related pericarditis: Clinical case series
    Chye, Adrian M. M.
    Nordman, Ina I. C.
    Sverdlov, Aaron L. L.
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2022, 9
  • [45] Therapeutic and Prognostic Implications of Immune-Related Adverse Events in Advanced Non-Small-Cell Lung Cancer
    Daniello, Lea
    Elshiaty, Mariam
    Bozorgmehr, Farastuk
    Kuon, Jonas
    Kazdal, Daniel
    Schindler, Hannah
    Shah, Rajiv
    Volckmar, Anna-Lena
    Lusky, Fabienne
    Diekmann, Leonore
    Liersch, Stephan
    Faehling, Martin
    Muley, Thomas
    Kriegsmann, Mark
    Benesova, Karolina
    Stenzinger, Albrecht
    Thomas, Michael
    Christopoulos, Petros
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [46] Immune-related adverse events with immune checkpoint inhibitors in thoracic malignancies: focusing on non-small cell lung cancer patients
    Remon, Jordi
    Mezquita, Laura
    Corral, Jesus
    Vilarino, Noelia
    Reguart, Noemi
    JOURNAL OF THORACIC DISEASE, 2018, 10 : S1516 - S1533
  • [47] Extensive-Disease Small-Cell Lung Cancer With Severe Immune-Related Adverse Events Due to Atezolizumab Maintaining a Complete Response for Two Years: A Case Report
    Kudo, Sayaka
    Yokoo, Keiki
    Tanaka, Nao
    Yamada, Gen
    Kitamura, Yasuo
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (03)
  • [48] Immune-related adverse events in non-small cell lung cancer: Occurrence, mechanisms and therapeutic strategies
    Lin, Xuwen
    Xie, Mei
    Yao, Jie
    Ma, Xidong
    Qin, Lin
    Zhang, Xu-Mei
    Song, Jialin
    Bao, Xinyu
    Zhang, Xin
    Zhang, Yinguang
    Liu, Yiming
    Han, Wenya
    Liang, Yiran
    Jing, Ying
    Xue, Xinying
    CLINICAL AND TRANSLATIONAL MEDICINE, 2024, 14 (03):
  • [49] Association between skin immune-related adverse events (irAEs) and multisystem irAEs during PD-1/PD-L1 inhibitor monotherapy
    Atsushi Yamaguchi
    Yoshitaka Saito
    Katsuya Narumi
    Ayako Furugen
    Yoh Takekuma
    Naofumi Shinagawa
    Yasushi Shimizu
    Hirotoshi Dosaka-Akita
    Mitsuru Sugawara
    Masaki Kobayashi
    Journal of Cancer Research and Clinical Oncology, 2023, 149 : 1659 - 1666
  • [50] Immune-related pulmonary toxicities of checkpoint inhibitors in non-small cell lung cancer: Diagnosis, mechanism, and treatment strategies
    Guo, Xinyu
    Chen, Shi
    Wang, Xueyan
    Liu, Xiaowei
    FRONTIERS IN IMMUNOLOGY, 2023, 14
12345